Back to Results

Evaluation of Upadacitinib for Vitiligo

Title

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Non-Segmental Vitiligo
Therapeutic Area Vitiligo
Principal Investigator David Rosmarin, MD
Min Age 18 Years
Max Age 65 Years
Gender Any
Contact Nicole Dumont
617-636-7462
ndonovan1@tuftsmedicalcenter.org
More Information https://clinicaltrials.gov/ct2/show/NCT04927975

Overview

The primary objective of this study is to evaluate the safety and efficacy of upadacitinib for the treatment of adult subjects with NSV.

Study Details

Inclusion Criteria

  • Clinical diagnosis of active or stable vitiligo made by a dermatologist
  • Stop all other treatments for vitiligo from screening through the final follow up visit

Exclusion Criteria

  • Subjects must not have previously been treated with any topical or systemic JAK inhibitor
  • Use of biologic or investigational therapy or procedure within 12 weeks prior to Visit 0

Study Requirements

Study is expected to last up to 14 months. This includes a 35-day screening period, a 24-week double blind treatment period (Period 1), a 28-week blinded long-term extension (Period 2), and a 30-day follow-up period.